Clinical trials: CDA
Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation
CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
For patients with refractory acute leukemia, allogeneic stem cell transplantation is the only curative therapy. Only 20% of patients may achieve long-term survival mostly due to relapse or nor-relapse mortality (NRM).
- Trial name
- NCT03882203
- Testing
- CLAGE-FluBu
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Leukemia, Monocytic, Acute, Pediatric AML
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells.
- Trial name
- SCCLG-M5 (NCT05313958)
- Testing
- Cladribine, G-CSF, Cytarabine
- Where
- 9 sites in China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sexual Trauma
Recovery-oriented Group Therapy for Veteran Men With Military Sexual Trauma
VA has identified military sexual trauma (MST) as one of its highest priorities. MST is associated with increased prevalence of PTSD and depression, substance use disorders, suicide, difficulties maintaining relationships and…
- Trial name
- NCT06741202
- Testing
- Men's MST Group, Present-Centered Group Therapy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Patients With Thalassemia Intermedia,, Congenital Dyserythropoietic Anemia Type I
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis
Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin…
- Trial name
- GDF 15 (NCT01201135)
- Volunteers
- 80 people
- Sponsor
- Wolfson Medical Center
Multiple Sclerosis
Oral Cladribine B-cell Study
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
- Trial name
- NCT06415864
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
Acute Myeloid Leukemia
CAV Regimen for R/R AML
This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT05657639
- Testing
- CAV Regimen, MEC Regimen
- Where
- China
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Patient Safety
An Intervention to Impact Cardiovascular Implantable Electronic Device Lead Models Implanted in Veterans
This study will evaluate if an intervention using academic detailing and audit and feedback impacts the specific pacemaker or implantable cardioverter-defibrillator (ICD) lead models implanted in Veterans.
- Trial name
- Veteran CIEDs (NCT05062434)
- Testing
- Academic detailing and audit and feedback intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the…
- Trial name
- NCT00371735
- Testing
- chlorproguanil-dapsone-artesunate, chlorproguanil-dapsone
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
Sulfadoxine-pyrimethamine is the current first-line therapy for uncomplicated malaria in Malawi. Significant resistance of the P.
- Trial name
- NCT00164359
- Testing
- Amodiaquine plus artesunate, chlorproguanil-dapsone plus artesunate
- Where
- 3 sites in Malawi
- Volunteers
- 212 people
- Sponsor
- Centers for Disease Control and Prevention
Refractory Acute Leukemia, Relapsed Acute Leukemia
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.
- Trial name
- NCT06474663
- Testing
- Cladribine, Cytarabine, Sorafenib
- Sponsor
- M.D. Anderson Cancer Center
Langerhans Cell Histiocytosis of Lung
Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis
ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5 days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary Langerhans cell histiocytosis and impairment…
- Trial name
- ECLA (NCT01473797)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
To explore the efficiency and safety of CLAG regimen in R/R ALL
- Trial name
- NCT05578378
- Testing
- Cladribine, Fludarabine
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Prediabetes
INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)
This study will evaluate a VA MyHealtheVet Secure Messaging intervention that uses different intervention messaging strategies designed to increase engagement in behaviors to prevent type 2 diabetes.
- Trial name
- INVENT (NCT03403231)
- Testing
- INVENT Secure Messaging Intervention
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development